A neuroscience group cleared an unlisted 11-mer for IACUC-reviewed in vivo work in seven weeks
An academic neuropharmacology group had a cognitive-pathway peptide that existed in no reference database and needed it characterized tightly enough to pass IACUC review for rodent intranasal dosing. Working from the bare sequence, the lot reached release-grade in seven weeks.
Published May 10, 2026 · Anonymized research-buyer story
Sequence brief → commercial batch
7 weeks
Pilot batch validation time
4 business days
Measured HPLC purity
≥99.2%
Endotoxin spec
<0.1 EU/mg
Challenge
An early in vitro paper from the group had described an 11-residue peptide proposed to act on a specific neuropeptide receptor. Moving to the in vivo phase — intranasal rodent dosing across a 12-week protocol — meant producing far more material than the department's own synthesis core could turn around on schedule. The sticking point for the Principal Investigator was identity assurance rather than throughput: because the sequence appeared in no reference database, the IACUC-reviewed protocol needed batch-level endotoxin and microbial-limit data plus an LC-MS/MS sequence read, since an intact-mass figure alone could not stand as proof of identity for an unlisted molecule.
Approach
A mutual NDA was countersigned the next business day, and Lyochem opened with a 500 mg pilot carrying the complete packet: HPLC at ≥99.2 % measured purity, ESI-MS placing the modified mass within 0.3 Da of theoretical, a full b/y-ion LC-MS/MS ladder, LAL endotoxin under 0.1 EU/mg, and USP <61>/<62> microbial limits. The group's own QC signed off the pilot in four business days. A 10 g commercial lot was then synthesized alongside the lab's validation work rather than after it, and both lots were held under stability monitoring spanning the dosing-protocol window to confirm potency held.
Outcome
From bare sequence to a validated commercial lot took seven weeks end to end — three for the pilot, four for the production batch. The animal study began on schedule, and the group's resulting paper cited Lyochem as the bulk-active source together with the per-batch endotoxin and microbial-limit figures the journal's methods section had treated as a mandatory disclosure.
“For an 11-mer that isn't in any database, the tandem-MS sequence read was the whole ballgame — an intact mass left more identity ambiguity than an IACUC protocol can carry. Getting the full ion-ladder coverage on the release lot was precisely what our methods section had to document.”